Comparative Pharmacology
Head-to-head clinical analysis: EMCYT versus GLEOSTINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMCYT versus GLEOSTINE.
EMCYT vs GLEOSTINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estramustine is a combination of estradiol and nitrogen mustard. The estradiol moiety targets the drug to cells expressing estrogen receptors, while the nitrogen mustard alkylates DNA, inhibiting cell division primarily in prostate cancer cells.
GLEOSTINE (lomustine) is a nitrosourea alkylating agent that crosslinks DNA and RNA, inhibiting DNA synthesis and repair. It is cell cycle phase-nonspecific.
Estramustine phosphate sodium: 14 mg/kg/day orally in 3-4 divided doses, typically 140 mg four times daily. Administer on an empty stomach (1 hour before or 2 hours after meals).
130 mg/m2 orally every 6 weeks as a single dose; alternatively, 75 mg/m2 orally every 3 weeks.
None Documented
None Documented
Terminal half-life of estramustine phosphate: ~20 hours; estromustine: ~14 hours; clinical context: supports daily dosing with accumulation over 5-7 days
16-48 hours (terminal), with an active metabolite half-life of up to 5 days, requiring dose adjustment for renal impairment
Renal: primarily as estramustine phosphate, estromustine, and estradiol; <1% as unchanged drug; fecal: ~15%
Renal: 60% (as metabolites), Fecal: <5% (unchanged and metabolites), Biliary: minimal
Category C
Category C
Alkylating Agent
Alkylating Agent